리포트 아카이브
전체 리서치
45페이지 중 9페이지 · 리포트 1080건
42/100
Sanofi SA: A Pure-Play in Transition, Still Proving Life After Dupixent
Sanofi is a French pure-play biopharma built around immunology, vaccines, and rare disease after ceding control of Opella. Dupixent alone reached 15.714 billion EUR of 2025 sales, about 36% of group revenue, and still grew 30.8% in Q1 2026, yet the market withholds a growth multiple until a post-Dupixent bridge is proven ahead of the roughly 2031 patent cliff. Rating Hold: a cleaner, cash-generative business at a cheapish multiple with 8.089 billion EUR of 2025 free cash flow, but no wide margin of safety on the hard part of the story.
45/100
BioMarin Pharmaceutical: A Rare-Disease Cash Engine in Transition
BioMarin is a profitable rare-disease biopharma whose enzyme franchise generated about 2.106 billion USD of 2025 revenue and funds the company, while VOXZOGO (926.9 million USD) drives both growth and sentiment. The Amicus acquisition diversified the portfolio into Fabry and Pompe disease and lifted 2026 revenue guidance to 3.825-3.925 billion USD, yet weekly and oral achondroplasia rivals from Ascendis and BridgeBio keep the margin of safety thin. Rating Hold: cash generation and Amicus diversification make BioMarin sturdier than sentiment implies, but VOXZOGO competition caps the upside at today's price.
36/100
Panasonic Holdings: Better Business, Priced Ahead of Proof
Panasonic Holdings is a diversified Japanese electronics group whose earnings base is still mature B2B and appliance operations, while batteries and AI-infrastructure products drive the growth narrative. FY2026 sales were ¥8.05 trillion across six segments, but ROE fell to 3.8% on ¥174.5 billion of restructuring charges, and the shares are up about 68% in 2026 on an AI-infrastructure rerating that capitalizes one hot battery-and-data-center engine across the whole group. Rating Hold: the business mix is genuinely improving, but at ¥4,540 the price already discounts most of the battery, AI-infrastructure, and restructuring upside, leaving no margin of safety against a conservative fair value near ¥2,400-¥2,690.
47/100
Symrise: A High-Quality Compounder Now Priced for Delivery, Not Discovery
Symrise is a scaled, oligopolistic flavors-and-fragrances and nutrition platform that gets paid for being embedded in customers' everyday products, with 2025 sales of €4.93 billion, a 21.9% adjusted EBITDA margin and record €780 million of business free cash flow. The 2026 question is delivery, not discovery: organic growth has cooled from 8.7% in 2024 to low single digits in 2025 and slightly negative in Q1 2026, yet cash conversion, leverage and margin quality all improved, so the franchise is intact while the near-term growth premium is not obviously earned. Rating Hold: a high-quality compounder whose €88.16 price already reflects most of the self-help and recovery, with a more comfortable margin of safety only in the high-€50s to mid-€60s.
47/100
JD.com: A Stronger Retail Core Discounted for the Cost of Transition
JD.com is China's largest self-operated online retailer, built on a supply-chain-first model spanning first-party retail, marketplace services, logistics, health and industrial procurement. Its retail core is strengthening, with JD Retail operating margin up to 5.6% in Q1 2026 and net service revenue growing 20.6% against just 1.0% product growth, yet group profit and cash conversion are obscured by heavy food-delivery and overseas investment, while listed-subsidiary stakes worth about US$17.7 billion anchor a sum-of-the-parts case. Rating Cautious Buy: the market discounts the cost of transition more than it credits a stronger retail core, large buybacks and visible listed stakes.
46/100
FUJIFILM Holdings: A Proven Reinventor Now Tested on Returns, Not Survival
FUJIFILM Holdings is a diversified Japanese technology group earning ¥3.36 trillion of FY2026 revenue across healthcare and Bio CDMO, semiconductor materials, imaging (instax) and office systems. Electronics and Imaging already supply about ¥260.9 billion, roughly three-quarters of segment operating profit, yet Healthcare ROIC is only 1.6%, FY2026 free cash flow is negative amid a capex bulge, and owner earnings near 23 times sit well above the 15.7 times headline P/E. Rating Hold: the transformation from film survivor to multi-engine compounder is real, but healthcare returns and owner earnings still lag the price, leaving no margin of safety until below ¥2,650.
49/100
ACM Research: A Credible China Semicap Franchise, a Demanding Holdco Structure
ACM Research is a Nasdaq-listed holding company whose value is dominated by its roughly 73.6%-owned, Shanghai-listed subsidiary ACM Shanghai, built on a single-wafer wet-cleaning franchise now broadening into plating, furnace, track and PECVD. The parent trades at a steep discount to the quoted value of that stake, yet the A-share quote is already rich, four customers make up 52.2% of 2025 revenue, and first-quarter 2026 free cash flow was negative 52.1 million USD. Rating Hold: strong China semicap execution is real, but at 104.50 USD the price offers too little protection against cash-conversion, policy and holdco-structure risk.
49/100
85Buffett
Bentley Systems: Durable Infrastructure Compounder, Thin Margin of Safety
Bentley Systems is a specialized infrastructure-engineering software vendor whose economic engine is a recurring estate embedded in civil, utility, and owner-operator workflows, with $1.495 billion ARR, 93% recurring revenue, 99% account retention, and 109% net retention. Full-year 2025 revenue rose 11.0% to $1.502 billion and free cash flow reached $520.2 million, yet a dual-class structure leaves the Bentley Control Group with about 62.8% of voting power and the $30 price sits roughly at conservative fair value. Rating Hold: a high-quality, sticky compounder whose cash conversion the headline P/E understates, but founder control and a thin margin of safety make a fresh buy more attractive below $25.
44/100
Black Sesame International: Credible Challenger, Unproven Cash Conversion
Black Sesame is a fabless designer of automotive compute SoCs, selling ADAS chips and bundled solutions; 2025 revenue rose 73% to RMB822 million, yet it stays deeply loss-making with R&D near 1.7x sales. It has crossed the technical-credibility threshold (A1000 shipping in Geely, BYD and FAW models) but not the cash-conversion one, leaning on repeated 2025-2026 equity raises. Rating Hold: real commercialization exists, but recurring dilution and negative owner earnings cap valuation support, with a true margin of safety only below about HK$6.
57/100
88Buffett
Belimo Holding: AI 냉각의 긴 활주로를 이미 가격에 반영한 프리미엄 HVAC 컴파운더
Belimo는 난방, 냉방, 환기를 조절하는 액추에이터, 제어 밸브, 센서, 계량기 등 HVAC 필드 디바이스 분야의 스위스 순수 플레이 리더로, 시공·개보수 채널을 통해 매출의 약 60%, OEM 채널을 통해 약 40%를 판매하며, 자사가 공급하는 통합 빌딩 자동화 대기업들과는 경쟁하지 않는다. 2025년 매출은 현지 통화 기준 23.3% 증가한 CHF 11.208억을 기록했으며, EBIT 마진 20.8%, ROIC 27.8%를 기록했다. 매출의 약 17%를 차지하는 AI 데이터센터 액체 냉각이 내구성 있는 에너지 효율 개보수 프랜차이즈 위에 두 번째 성장 엔진이 되었지만, 후행 이익의 약 61배에 거래되는 주가는 자체 과거 범위의 상단 부근에 있다. 등급은 관찰: 진정으로 뛰어난 니치 컴파운더이지만, 주가는 이미 탁월함과 긴 AI 냉각 활주로를 모두 반영하고 있어, 더 매력적인 진입점은 대략 CHF 480 아래에서만 나타난다.
53/100
80Buffett
Sika AG：순환적 에어포켓 속 고품질 컴파운더
Sika는 건설용 화학제품(혼화제, 방수재, 실란트, 지붕재, 산업용 접착제) 분야의 세계적 리더로, 100개국 이상 400개 이상의 공장을 통해 현지에 맞춘 시스템을 판매하며, Parex와 MBCC 같은 볼트온 M&A를 사업 모델에 편입시켰다. 2025년 매출은 스위스 프랑 강세와 건설 경기 둔화로 4.8% 감소한 112.0억 스위스프랑을 기록했지만, 현지 통화 기준 성장은 플러스를 유지했고 소재 마진은 54.9%로 상승했으며 MBCC 시너지는 1.82억 스위스프랑에 달했다. 등급은 보유: 일류 시리얼 인수자형 컴파운더가 순환적 에어포켓에 갇혀 있지만, 직전 이익의 약 26배라는 밸류에이션은 오가닉 성장이 회복되기도 전에 마진 회복분의 상당 부분을 이미 반영하고 있다.
51/100
81Buffett
NARI Technology: Grid-Control Franchise, Quality Already Priced
NARI is the dominant listed proxy for China's grid-control layer: dispatch software, relay protection, UHV control and energy-management systems built around State Grid. 2025 revenue reached RMB 66.23bn with operating cash flow of RMB 12.77bn, yet revenue is outgrowing profit as the mix shifts toward lower-margin storage and outside-grid work. Rating Hold: a high-quality policy-cycle compounder whose roughly 22x trailing valuation leaves little margin of safety against further mix dilution.
48/100
AVIC Jonhon Optronic: Defense-Grade Interconnect Leader, Recovery Already Priced
AVIC Jonhon is a Chinese high-reliability interconnect maker whose defense-grade connector core still carries the business (connectors are 98.5% of revenue) while EVs, data centers and optics become the larger growth engine. 2025 revenue edged up 3.4% to RMB 21.39 billion but attributable profit fell 35.6% to about RMB 2.16 billion as defense demand softened and gold, copper and silver costs surged, and at RMB 42.69 the stock already trades on a mid-40s trailing multiple that discounts a recovery while cash conversion stays weak. Rating Hold: the franchise is intact and a rebound is plausible, but today's price pre-spends most of it with no margin of safety.
53/100
80Buffett
Straumann Holding AG: 부담스러운 가격의 덴탈 플랫폼 리더
Straumann은 전문 치과 분야의 글로벌 리더로, 프리미엄 임플란트 제조사에서 임플란트·디지털 워크플로우·생체재료·보철물·투명 교정장치를 아우르는 멀티브랜드·멀티가격대 그룹으로 성장한 스위스 플랫폼 기업이다. 2025년 매출은 CHF 26.1억이며 CHF 60억 규모 임플란트 시장의 약 35%를 점유하고 있다. 프랜차이즈 품질은 진짜다(ROCE 30.6%, 자기자본비율 57.6%, 10년에 걸친 점유율 확대). 다만 밸류티어·디지털 비중이 커지면서 매출총이익률은 76.2%에서 68.6%로, 잉여현금흐름률은 21.8%에서 11.1%로 하락했고, 주가는 코어이익 대비 약 35.8배, 잉여현금흐름수익률 1.7%에 거래되고 있다. 등급은 보유: 긴 성장 활주로를 가진 고품질 컴파운더이지만, 주가는 이미 다음 마진·생태계 국면의 상당 부분을 반영하고 있어 안전마진이 거의 남아있지 않다.
52/100
84Buffett
GSK plc: Rebuilt Biopharma, Racing the Patent Cliff
GSK plc is a UK biopharma rebuilt around vaccines and specialty medicines after the 2022 Haleon demerger, with 2025 sales of £32.7bn anchored by Shingrix and the ViiV HIV franchise. Specialty medicines now drive growth (£13.5bn, +14% CER in Q1 2026) and core operating profit rose 11% to £9.8bn, yet the whole story hinges on replacing the dolutegravir HIV cliff in 2028–2030 before it arrives. Rating Hold: a genuinely higher-quality franchise at roughly 11.6x core earnings, but the price already assumes much of the patent-cliff bridge, leaving little margin of safety.
60/100
72Buffett
Sungrow Power Supply: 경기순환 껍질 속의 고품질 성장
Sungrow Power Supply는 태양광 인버터와 에너지 저장 시스템 분야의 창업자 주도형 글로벌 리더로, 해외 매출이 2025년 매출의 60.7%를 차지했고 저장 사업은 매출의 41.9%를 차지하는 최대 부문이 되었다. 영업현금흐름은 CN¥169억까지 증가했고 매출채권도 개선되었지만, 2026년 1분기 매출은 18.3% 감소, 이익은 40.1% 감소하며 품질 스토리 이면의 급격한 마진 믹스 순환성을 드러냈다. 등급 보유: 진정한 품질 성장 프랜차이즈이지만 현재 가격은 실행 오류에 대한 안전마진이 거의 없는 프리미엄 수준이다.
U.S. Market Close Daily | 2026-06-26
Major indexes edged lower as an AI and semiconductor reset outweighed better breadth, cheaper oil, and lower Treasury yields.
42/100
94Buffett
Games Workshop: An Exceptional Warhammer Compounder, Priced for Continued Excellence
Games Workshop is the vertically integrated owner of the Warhammer universe, designing, manufacturing and selling miniatures, paints, books and licensed media from a single UK creative stack at returns on capital few public companies reach. FY2025 delivered £617.5m of total revenue and £262.8m of profit before tax, and FY2026 is guided higher even as the volatile licensing line steps down from £52.5m to at least £30m. Rating Hold: an exceptional IP compounder whose roughly 35x earnings multiple already prepays years of flawless execution, leaving no margin of safety at £217.
38/100
Simulations Plus: A Credible Drug-Modeling Specialist, Now Priced as a Near-Cash Deal Stock
Simulations Plus builds scientifically trusted drug-development modeling software (GastroPlus, MonolixSuite, ADMET Predictor, DILIsym), but its revenue mix has drifted toward lower-margin services since the 2024 Pro-ficiency acquisition, which pulled FY2025 gross margin to 58% and triggered a $77.2m impairment. On 2026-06-26 the equity trades as a near-cash event security: Altaris' agreed $18.50-per-share takeout caps upside just above the $18.14 close, while a broken deal would reopen real downside. Rating Avoid: a thin-spread cash-deal security whose unresolved software-mix question still sits underneath the transaction.
38/100
Carl Zeiss Meditec: A High-Grade Ophthalmology Franchise Forced to Relearn Its Operating Model in China
Carl Zeiss Meditec is a premium German ophthalmology and microsurgery franchise where ophthalmology drives about 77% of sales and recurring revenue has climbed from 9% two decades ago to roughly 50%. A simultaneous China VBP shock and weak Americas equipment demand crushed H1 FY2025/26 adjusted EBITA margin to 6.1% from 10.7%, and the shares have fallen more than 80% from their 2021 peak to 27.96 euros. Rating Watch: a high-quality medtech franchise in a real trough, but the China relisting and margin-restoration bridge is still too unproven for a clean entry, with the ideal buy zone at 24 to 26 euros.
45/100
77Buffett
SAP: A High-Quality Incumbent Late in Its Cloud Migration, Now Priced for Proof Rather Than Possibility
SAP is the incumbent enterprise-applications vendor migrating its captive ERP installed base from license-and-support to cloud subscriptions, where process centrality keeps converting into long-duration economics. In 2025 cloud revenue reached 21.0 billion euros and predictable revenue 86%, with total cloud backlog of 77.3 billion euros, yet FY2026 guidance for slightly decelerating current-backlog growth reset the stock more than 50% below its early-2025 peak to about 21.5x earnings. Rating Hold: the cloud transition is genuinely working and the franchise is high quality, but at today's price the market already asks for proof rather than possibility, with the ideal buy zone at 95 to 101 euros.
42/100
Shimano: A Fortress Cycling Franchise in a Real Trough, But the Price Already Pays for the Repair
Shimano is a century-old Japanese precision manufacturer whose bicycle drivetrain and braking franchise still drives roughly three-quarters of group sales, with fishing tackle the resilient second engine. Group operating income has fallen from a 169.2 billion yen pandemic peak in 2022 to a guided 47.0 billion yen in 2026 (margin near 10% against a historical 20% to 25%), and at 17,340 yen (about 35x guided earnings) the price already discounts much of the eventual repair, leaving no margin of safety. Rating Hold: a fortress-quality franchise in a real but uncertain trough, where the moat is intact yet the entry price is not yet compelling, with the ideal buy zone at 12,000 to 14,000 yen.
51/100
83Buffett
Hengrui Pharmaceuticals: A Fortress Innovation Platform, But RMB 50 Already Pays for the Upgrade
Hengrui Pharmaceuticals is China's largest listed innovative-drug platform, still earning mainly from domestic drug sales while its valuation increasingly rests on converting self-funded R&D into commercial franchises and recurring overseas licensing income. 2025 revenue reached RMB 31.63 billion with net profit of RMB 7.71 billion and a fortress balance sheet holding RMB 40.16 billion of cash, yet at RMB 50.04 (about 41x trailing earnings) the price sits above the conservative fair value and leaves no margin of safety. Rating Hold: a rare high-quality China pharma platform already priced for an innovation-monetization upgrade it has not yet fully earned.
U.S. Market Close Daily | 2026-06-25
U.S. stocks closed mixed in a sector-rotation tape as semiconductor strength offset pressure from mega-cap consumer technology and sticky inflation kept rate risk in focus.